Clinical Therapeutics/New Technology-Oral Agents

Clinical Therapeutics/New Technology-Oral Agents

You have access
Probable Dapagliflozin-Associated Acute Pancreatitis
Ashlee D. Barrett, Mason A. Pitts, Elizabeth M. Myers, Jeremy L. Johnson

Diabetes Spectrum Sep 2021, ds210025; DOI: 10.2337/ds21-0025
Open Access
6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
American Diabetes Association

Diabetes Care Jan 2021, 44 (Supplement 1) S73-S84; DOI: 10.2337/dc21-S006
You have access
Effect of Maternal Metformin Treatment in Pregnancy on Neonatal Metabolism: Evidence From Newborn Metabolic Screening
Jane Estrella, Veronica Wiley, David Simmons, Tien-Ming Hng, Mark McLean

Diabetes Care Sep 2021, dc210327; DOI: 10.2337/dc21-0327
You have access
Second-Line Therapy for Type 2 Diabetes Management: The Treatment/Benefit Paradox of Cardiovascular and Kidney Comorbidities
Rozalina G. McCoy, Holly K. Van Houten, Pinar Karaca-Mandic, Joseph S. Ross, Victor M. Montori, Nilay D. Shah

Diabetes Care Oct 2021, 44 (10) 2302-2311; DOI: 10.2337/dc20-2977
Open Access
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
Ofri Mosenzon, Stephen D. Wiviott, Hiddo J.L. Heerspink, Jamie P. Dwyer, Avivit Cahn, Erica L. Goodrich, Aliza Rozenberg, Meir Schechter, Ilan Yanuv, Sabina A. Murphy, Thomas A. Zelniker, Ingrid A.M. Gause-Nilsson, Anna Maria Langkilde, Martin Fredriksson, Peter A. Johansson, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Marc S. Sabatine, Itamar Raz

Diabetes Care Aug 2021, 44 (8) 1805-1815; DOI: 10.2337/dc21-0076
You have access
Fenofibrate Use Is Associated With Lower Mortality and Fewer Cardiovascular Events in Patients With Diabetes: Results of 10,114 Patients From the Korean National Health Insurance Service Cohort
Sang-Ho Jo, Hyewon Nam, Jeongwoo Lee, Sojeong Park, Jungkuk Lee, Dae-Sung Kyoung

Diabetes Care Aug 2021, 44 (8) 1868-1876; DOI: 10.2337/dc20-1533
Open Access
Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015
Ian J. Neeland, Takatoshi Kasai, Silvio E. Inzucchi, Brian S. Wojeck, Henry K. Yaggi, Odd Erik Johansen

Diabetes Care Jun 2021, 44 (6) e137-e138; DOI: 10.2337/dci21-0009
Open Access
Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015
Shay Brikman, Guy Dori

Diabetes Care Jun 2021, 44 (6) e136; DOI: 10.2337/dc21-0310
Open Access
Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136
Roselle A. Herring, Fariba Shojaee-Moradie, Robert Garesse, Mary Stevenage, Nicola Jackson, Barbara A. Fielding, Agampodi Mendis, Sigurd Johnsen, A. Margot Umpleby, Melanie Davies, David L. Russell-Jones

Diabetes Care Mar 2021, 44 (3) e61; DOI: 10.2337/dci20-0072
Open Access
Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136
Geremia B. Bolli, Francesca Porcellati, Paola Lucidi, Carmine G. Fanelli

Diabetes Care Mar 2021, 44 (3) e59-e60; DOI: 10.2337/dc20-2575

Main menu

User menu

Search

Clinical Therapeutics/New Technology-Oral Agents

Pages

Navigate

More Information

Other ADA Resources